CurrentPremera BluecrossPolicy N/A

Ablative Nerve Procedures for Chronic Headache and Facial Pain - Coverage Criteria

This policy governs coverage of ablative procedures (chemical neurolysis, cooled RFA, cryoneurolysis/cryoablation, pulsed RFA, and RFA) when used to treat chronic headaches (including chronic migraine, tension-type, cluster, cervicogenic), occipital neuralgia, and persistent idiopathic facial pain (PIFP); it informs providers about investigational status and coding. Affects providers and facilities submitting claims to Premera Blue Cross.

Policy Summary

PayerPremera Bluecross

PolicyAblative Nerve Procedures for Chronic Headache and Facial Pain - Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateApr 1, 2026

Next Review DateApr 1, 2026

Key ActionVerify member benefits and submit prior authorization with documentation of failed conservative therapies and diagnostic nerve block response where applicable.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalInvestigational stance

5Procedures named

6CPT codes listed

15+/moChronic migraine threshold

Low

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations

Investigational — All listed indications and modalities

Ablative nerve procedures are considered investigational for the following indications and modalities:

Investigational indications and procedures: Ablative procedures for the treatment of chronic migraines, chronic tension-type headaches, chronic cluster headaches, cervicogenic headaches, occipital neuralgia, and persistent idiopathic facial pain (PIFP) are considered investigational.

Procedures include, but are not limited to, chemical neurolysis (chemodenervation), cooled radiofrequency ablation, cryoneurolysis/cryoablation, pulsed radiofrequency, and radiofrequency ablation (RFA).

Investigational / Not Established

Summary conclusion from evidence review

Investigational status for ablative interventions in headache/facial pain: Ablative procedures including chemical neurolysis, cryoablation/cryoneurolysis, pulsed radiofrequency, conventional RFA, and cooled RFA for treatment of chronic headache syndromes, occipital neuralgia, and persistent idiopathic facial pain are considered investigational due to insufficient high-quality evidence demonstrating net health benefit.

Available studies include randomized trials, prospective and retrospective studies, and case reports but are limited by small size, lack of controls or blinding, short follow-up, and methodological heterogeneity.

Investigational / Not medically necessary

Policy coverage determination

Investigational interventions: Ablative procedures including but not limited to chemical neurolysis, cryoablation, pulsed radiofrequency, and radiofrequency ablation for the treatment of chronic headaches (chronic migraine, chronic tension-type headache, chronic cluster headache, cervicogenic headache), occipital neuralgia, and persistent idiopathic facial pain are considered investigational and not medically necessary for these indications.

Policy history and summary maintain investigational stance after literature reviews through January 27, 2026.

This policy explicitly classifies ablative nerve procedures for the treatment of chronic headaches (including chronic migraine, chronic tension‑type, and chronic cluster headaches), cervicogenic headache, occipital neuralgia, and persistent idiopathic facial pain (PIFP) as investigational. No covered indications for these procedures in the head, neck, or facial pain diagnoses are specified in this section of the policy; therefore use of these ablative techniques for these indications is not supported as medically necessary under this policy.

Although some cooled radiofrequency systems (for example, the COOLIEF device) have received FDA clearance for creating lesions of the genicular nerves to treat knee osteoarthritis, that regulatory clearance applies to genicular nerve ablation for joint pain and does not establish efficacy for head, neck, or facial pain indications. The policy therefore treats cooled radiofrequency for chronic headache and facial pain as investigational despite device clearances for other anatomic uses.

This medical policy applies to Premera Blue Cross commercial and other non‑Medicare lines of business. This policy does not apply to Medicare Advantage. Providers should verify member benefits and applicable coverage rules for Medicare Advantage separately.

The evidence base for ablative procedures in chronic headache syndromes, occipital neuralgia, and PIFP is limited and heterogeneous. While randomized, prospective, retrospective, and case series reports exist and some studies report short‑term pain improvement and reduced medication use, the overall body of literature lacks definitive, high‑quality trials demonstrating consistent net health benefit.

Limitations across studies include small sample sizes, lack of randomized and blinded controls, single‑center or retrospective designs, variable inclusion criteria (for example, selection of diagnostic block responders), and short duration of follow‑up. These methodological concerns reduce confidence in efficacy estimates and contribute to the conclusion that current evidence is insufficient to support routine use.

Given the limited and low‑quality evidence, ablative procedures including chemical neurolysis, cryoneurolysis/cryoablation, pulsed radiofrequency, cooled radiofrequency, and radiofrequency ablation (RFA) for chronic headache disorders, occipital neuralgia, and persistent idiopathic facial pain are considered investigational (not covered as medically necessary) for these indications.

Coding and Billing

CPT codes referencedCPT

62281	Injection/infusion of neurolytic substance (e.g., alcohol, phenol, iced saline solutions), with or without other therapeutic substance; epidural, cervical or thoracic.
64600	Destruction by neurolytic agent, trigeminal nerve; supraorbital, infraorbital, mental, or inferior alveolar branch.
64633	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint.
64634	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, each additional facet joint (List separately in addition to code for primary procedure).
64640	Destruction by neurolytic agent; other peripheral nerve or branch.
64999	Unlisted procedure, nervous system (used to report RFA).

FDA device product codes mentionedmixed

GXD	FDA product code for radiofrequency lesion generators
GXI	FDA product code for radiofrequency lesion probes

Coding notes / AdditionsCPT

64999

Unlisted procedure, nervous system (added to report RFA)

inv-13: Chronic migraine frequency diagnostic threshold

Diagnostic threshold15 or more headache days per month lasting at least 4 hours per day for more than 3 months

Population prevalence noteChronic migraine affects about 2% of the world population

Associated featuresMay be accompanied by photophobia, phonophobia, nausea and/or vomiting

Provider Requirements and Actions

Billing Rule

Coding and Authorization Note

Use the CPT codes listed below when submitting claims for ablative procedures; include appropriate documentation and prior authorization if required by the member's plan.

62281
64600
64633
64634
64640
64999

Prior Authorization

Investigational — Prior Authorization Recommended

Ablative procedures for chronic headaches, occipital neuralgia, and persistent idiopathic facial pain are classified investigational. Prior authorization is recommended before scheduling these procedures to avoid potential denial.

Conservative Treatment Prerequisites

Documentation of failed conservative therapies is relevant though no explicit duration or number of therapies is specified

Documentation of prior conservative therapies is relevant when considering ablative procedures, although the policy does not specify a required duration or exact number of failed therapies.

Conservative therapy documentation relevant: Documentation that conventional treatments (e.g., oral or injectable pharmacologic therapies, physical therapy, chiropractic care, or transcutaneous electrical nerve stimulation [TENS]) have failed is relevant to the evaluation of ablative procedures.

Policy text notes these procedures are proposed when conventional treatments have failed but does not impose explicit numeric or temporal requirements in this section.

Documented failure of appropriate conventional therapies and, where applicable, a positive diagnostic nerve block are generally expected before considering ablative procedures

Before considering ablative procedures, clinicians are generally expected to document failure of appropriate conventional therapies and, where applicable, a positive diagnostic nerve block.

Expectations before ablative procedures:

Definitions and Procedural Descriptions

inv-27: Chemical neurolysis (chemodenervation) — definition and agents

DefinitionApplication of a chemical destructive agent (e.g., phenol, ethyl alcohol, glycerol, or hypertonic saline) to a nerve to create a long-lasting or permanent interruption of neural transmission

Also known asChemical ablation, chemodenervation, or chemical denervation

Typical useUsually used to relieve pain

inv-28: Cooled radiofrequency ablation — definition and mechanism

DefinitionMinimally invasive method using a water-cooled electrode to deliver thermal RF energy, creating a larger lesion than conventional RF to deactivate pain-transmitting sensory nerves

MechanismIonic heating from charged water molecule friction plus cooling targets pain-transmitting nerves while limiting excessive heating

Treatment Frequency and Limits

inv-38: Frequency/technical note — some CPT codes describe imaging guidance; policy lists codes without specifying frequency limits here

Coding noteSome CPT codes (e.g., 64633 and 64634) describe destruction-by-neurolytic-agent procedures performed with imaging guidance (fluoroscopy or CT)

Policy listingPolicy lists CPT codes for ablative procedures but does not specify frequency limits in this section

CPT codes referenced62281, 64600, 64633, 64634, 64640, 64999

inv-39: Frequency limits — no explicit frequency limits stated; studies referenced often included single treatments with varying follow-up

Frequency limits statementNo explicit frequency limits are stated for ablative procedures in this policy

Study frequency context

Imaging and Procedural Guidance

Billing Rule

Imaging guidance (fluoroscopy or CT) referenced for 64633/64634

Codes 64633 and 64634 describe destruction by neurolytic agent of paravertebral facet joint nerves and include imaging guidance (fluoroscopy or CT) in their code descriptions; imaging guidance is referenced for these procedures.

64633/64634: '...with imaging guidance (fluoroscopy or CT); cervical or thoracic...'
Fluoroscopy or CT referenced as imaging guidance per code description

Documentation Required

Imaging may be required to demonstrate cervical lesion for cervicogenic headache

When diagnosing cervicogenic headache, clinical and/or imaging evidence of a cervical spine disorder may be required to demonstrate a lesion that can cause headache; documentation of causation (including improvement after diagnostic blockade) is part of diagnostic confirmation.

Cervicogenic headache diagnostic support includes clinical/imaging evidence of a cervical disorder
Evidence of causation can include abolition of headache following diagnostic blockade

Background and Scope

Ablative nerve procedures are intended to interrupt peripheral pain signal transmission to reduce chronic pain. Modalities addressed by this policy range from chemical neurolysis (application of neurolytic agents) to thermal techniques such as cryoneurolysis, pulsed radiofrequency, conventional radiofrequency ablation (RFA), and cooled radiofrequency. Although their shared aim is reduction of peripheral sensory signaling to relieve headache or facial pain, the techniques differ in mechanism, expected duration of effect, and invasiveness, and none have demonstrated consistent, high‑quality evidence of net health benefit for the head, neck, or facial pain indications covered by this policy.

Not Covered Services

Not covered procedures under this policy include, but are not limited to, chemical neurolysis (chemodenervation), cooled radiofrequency ablation (cooled RFA/CRFA), cryoneurolysis/cryoablation, pulsed radiofrequency (PRF), and radiofrequency ablation (RFA) when performed for chronic migraines, chronic tension‑type headache, chronic cluster headache, cervicogenic headache, occipital neuralgia, and persistent idiopathic facial pain (PIFP). These interventions are classified as investigational for the listed chronic headache and facial pain indications.

Policy Summary

PayerPremera Bluecross

PolicyAblative Nerve Procedures for Chronic Headache and Facial Pain - Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateApr 1, 2026

Next Review DateApr 1, 2026

Key ActionVerify member benefits and submit prior authorization with documentation of failed conservative therapies and diagnostic nerve block response where applicable.

SourceLink

On This Page

Investigational procedures may be denied if submitted without prior authorization
Examples include chemical neurolysis, cooled RFA, cryoneurolysis, pulsed RF, and RFA

Billing Rule

Coding Update for RFA

CPT 64999 (Unlisted procedure, nervous system) may be used to report radiofrequency ablation (RFA) procedures when no specific CPT code applies. Submit full operative and device/procedure details with claims.

64999 — Unlisted procedure, nervous system (used to report RFA)
Provide detailed operative report and justification when using unlisted code

Denial Risk

Investigational Status May Trigger Denial

Because these interventions are investigational, claims for ablative procedures for the covered indications may be denied when documentation does not demonstrate medical necessity or when benefit limits do not permit investigational services.

Investigational status may trigger denial of claims
Denials likely when submitted for chronic migraine, tension-type, cluster, cervicogenic headaches, occipital neuralgia, or PIFP

Documentation Required

Diagnosis Confirmation Documentation

Diagnosis confirmation is required for cervicogenic headache, occipital neuralgia, and PIFP. For cervicogenic headache and occipital neuralgia, diagnostic local anesthetic blockade of the suspected nerve/structure with resulting pain relief is expected to confirm the diagnosis.

Cervicogenic headache: two anesthetic blocks of suspected generator at different times with pain relief consistent with anesthetic used
Occipital neuralgia: pain eased temporarily by local anesthetic block of affected occipital nerve(s)
PIFP: diagnosis of exclusion — recurring daily >2 hours/day for >3 months with normal neurological exam and dental causes excluded

Documentation Required

Required Clinical Documentation to Support Diagnosis

Clinical documentation must demonstrate: (1) clinical and/or imaging evidence of a cervical or neural lesion when applicable; (2) evidence of causation (e.g., temporal relation to cervical disorder, improvement with resolution of disorder, provocative maneuvers reproducing pain, or diagnostic blockade response); and (3) failure of conservative therapies.

Clinical/imaging evidence of disorder or lesion able to cause the headache
At least two indicators of causation for cervicogenic headache (see criteria) or positive diagnostic block for occipital neuralgia
Documentation of prior conservative therapies tried and failed (medications, physical therapy, chiropractic care, TENS, injectable therapies)

Note

Benefit Verification Recommended

Verify member benefits and coverage limitations with customer service prior to scheduling. Member contracts vary and investigational services may be excluded from coverage.

Contact Premera customer service to confirm benefit coverage and prior authorization requirements
Investigational designation may be excluded under some member plans

Documentation Required

Conservative Therapy Prerequisite (Context)

Ablative procedures should be considered only after conventional, nonablative treatments have failed. Document prior trials of oral/injectable pharmacotherapy, physical therapy, chiropractic care, and TENS or other conservative measures.

Conservative therapies attempted and failed must be documented before considering ablative interventions
Examples: oral and injectable medications, physical therapy, chiropractic care, TENS, and other standard nonablative measures

Note

Conservative-First Approach Suggested

Clinical practice guidelines and evidence summaries support a conservative-first approach — reserve ablative techniques for selected patients after nonablative treatments have failed and diagnostic confirmation is obtained.

Reserve ablative procedures for selected patients with confirmed diagnosis and failure of conservative therapy
High-quality randomized trials are lacking; use caution when considering ablative interventions

Documented failure of appropriate conventional therapies and, where applicable, a positive diagnostic anesthetic nerve block that produced meaningful pain relief are generally expected before considering ablative procedures for headache or facial pain syndromes.

Guidelines and study inclusion criteria referenced in the evidence summary commonly required prior conservative care and diagnostic blockade; these support a conservative-first approach.

Conservative treatment requirements placeholder (no label provided in inventory)

Conservative treatment requirement (placeholder): Conventional or established nonablative treatments should be attempted and documented as failed prior to considering ablative techniques; specific duration, number, or sequencing of therapies is not specified in this policy section.

Practice guidelines (ASA/ASRA) and study protocols cited in the evidence support reserving ablative procedures for selected patients after other care has failed; documentation expectations include clinical history and prior treatment trials.

Device exampleCoolief (Halyard Health) circulates water through the device to create a larger treatment area

inv-29: Cryoneurolysis (cryoablation) — definition and reversibility note

DefinitionFreezing target peripheral nerves using a small probe to temporarily block nerve conduction

Reversibility noteNitrous oxide–based cryoneurolysis (≈ -88.5°C) is usually reversible due to axon disruption with intact connective tissue allowing regeneration; liquid nitrogen–based cryoablation (≈ -195.8°C) may be irreversible due to endoneurium disruption

SynonymsCryodenervation, cryoablation, cryotherapy, cryoanalgesia

inv-30: Pulsed radiofrequency (PRF) — definition and non/neurodestructive intent

DefinitionNon- or minimally neurodestructive technique applying short bursts of radiofrequency energy that keep electrode temperature below the neurodestructive threshold (≈45°C)

IntentDesigned to avoid coagulation necrosis; mechanism of clinical effect is unclear

Delivery patternDelivered in short bursts (twice per second) followed by quiet phases allowing electrode cooling

inv-31: Radiofrequency ablation (RFA) — definition (coagulation necrosis)

DefinitionMinimally invasive method using a needle electrode and high-frequency electrical current to heat target nerve tissue, producing coagulation necrosis and destroying the nerve

MechanismThermal lesioning destroys peripheral sensory nerve endings to reduce pain signaling

TechniqueNeedle electrode inserted percutaneously into tissue around the target nerve with applied high-frequency current

inv-32: Radiofrequency ablation (RFA) — alternate definition/description

Alternate descriptionA minimally invasive technique using a needle electrode and high-frequency electrical current to heat and create coagulation necrosis of targeted nerve tissue to reduce peripheral sensory signaling and alleviate pain

Clinical goalAlleviation of pain via destruction of nerve tissue responsible for peripheral sensory signaling

Reporting noteCPT code 64999 may be used to report RFA (policy coding update) — see coding section

inv-33: Headache disorder definitions — summarized ICHD-3 diagnostic criteria for chronic headache types

Chronic migraineHeadaches on ≥15 days/month for >3 months, with at least 5 attacks on ≥8 days/month fulfilling migraine criteria; attacks lasting ≥4–72 hours when untreated

Chronic tension-type headache (TTH)Headache on ≥15 days/month for >3 months; bilateral, pressing/tightening quality, mild–moderate intensity; limited associated nausea/photophobia/phonophobia

Occipital neuralgiaParoxysmal shooting/stabbing pain in posterior scalp in distribution of occipital nerves, often eased temporarily by local anesthetic block

inv-34: Ablative procedures — examples list

Examples of ablative proceduresChemical neurolysis (chemodenervation)

Examples of ablative proceduresCryoneurolysis / cryoablation

Examples of ablative proceduresPulsed radiofrequency (PRF) and radiofrequency ablation (RFA), including cooled RFA

Studies referenced often included single treatments with varying follow-up durations

Implication for providersPolicy emphasizes investigational status rather than specifying repeat-treatment intervals